Vident Investment Advisory LLC increased its stake in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) by 14.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,724 shares of the biopharmaceutical company’s stock after acquiring an additional 961 shares during the period. Vident Investment Advisory LLC’s holdings in SAGE Therapeutics were worth $1,209,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. BlackRock Inc. increased its stake in SAGE Therapeutics by 9.6% in the 1st quarter. BlackRock Inc. now owns 3,774,283 shares of the biopharmaceutical company’s stock valued at $607,923,000 after buying an additional 330,112 shares during the last quarter. Fiera Capital Corp increased its stake in SAGE Therapeutics by 789.3% in the 2nd quarter. Fiera Capital Corp now owns 273,918 shares of the biopharmaceutical company’s stock valued at $42,876,000 after buying an additional 243,118 shares during the last quarter. American Century Companies Inc. increased its stake in SAGE Therapeutics by 63.6% in the 2nd quarter. American Century Companies Inc. now owns 527,062 shares of the biopharmaceutical company’s stock valued at $82,501,000 after buying an additional 204,831 shares during the last quarter. Point72 Asset Management L.P. increased its stake in SAGE Therapeutics by 381.1% in the 1st quarter. Point72 Asset Management L.P. now owns 102,600 shares of the biopharmaceutical company’s stock valued at $16,526,000 after buying an additional 139,100 shares during the last quarter. Finally, FMR LLC increased its stake in SAGE Therapeutics by 1.6% in the 2nd quarter. FMR LLC now owns 6,977,378 shares of the biopharmaceutical company’s stock valued at $1,092,169,000 after buying an additional 110,687 shares during the last quarter.

Several equities research analysts have issued reports on SAGE shares. BidaskClub upgraded shares of SAGE Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 30th. Stifel Nicolaus lifted their price target on shares of SAGE Therapeutics from $198.00 to $239.00 and gave the company a “buy” rating in a research note on Tuesday, August 7th. LADENBURG THALM/SH SH started coverage on shares of SAGE Therapeutics in a research note on Wednesday, June 6th. They issued a “buy” rating and a $230.00 price target on the stock. Morgan Stanley lifted their price target on shares of SAGE Therapeutics from $225.00 to $228.00 and gave the company an “overweight” rating in a research note on Friday, July 13th. Finally, Cowen reiterated a “buy” rating and issued a $207.00 price target on shares of SAGE Therapeutics in a research note on Thursday, June 14th. Two analysts have rated the stock with a sell rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. SAGE Therapeutics has an average rating of “Buy” and an average price target of $199.19.

SAGE Therapeutics stock opened at $145.13 on Tuesday. The stock has a market cap of $6.92 billion, a PE ratio of -20.47 and a beta of 2.90. SAGE Therapeutics Inc has a fifty-two week low of $59.57 and a fifty-two week high of $195.97.

SAGE Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($1.84) by $1.48. The firm had revenue of $90.00 million for the quarter. research analysts predict that SAGE Therapeutics Inc will post -7.37 earnings per share for the current fiscal year.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Featured Story: How Do You Calculate Return on Investment (ROI)?

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.